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Case Presentation 
The NIH describes angina as chest pain and 
discomfort that occurs if the heart muscle 
does not get enough oxygen rich blood. The 
pain associated with angina is often 
described as squeezing or pressure in the 
chest, the pain may radiate to the jaw, 
shoulders, arms, and neck (NIH, 2011). Signs 
and symptoms associated with refractory 
angina may vary significantly among 
patients. 
The patient may present with nausea, 
lethargy, increased shortness of breath, 
diaphoresis, dizziness, and generalized 
weakness. Women experience angina 
differently, typically presenting with jaw, 
neck, throat, abdominal or back discomfort. 
Diabetics may complain of increased 
shortness of breath, in the absence of pain 
(PubMed Health, 2010). 
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According to the literature, coronary 
heart disease (CHD) is responsible for 
370,000 deaths annually in the United 
States (Centers for Disease Control and 
Prevention [CDC], 2015).  A symptom 
commonly associated with CHD is 
angina (US Department of Health & 
Human Services, National Institute of 
Health, National Heart, Lung, and Blood 
Institute [NIH], 2011).   
An estimated 300,000 to 900,000 
patients in the United States have 
refractory angina pectoris (RAP), with 
nearly 100,00 new cases diagnosed 
yearly (Manchanda, Aggarwal, 
Aggarwal, & Soran, 2011). Kones 
describes refractory angina as 
continued angina class III/IV, in the non-
surgical candidate, with objective 
evidence of ischemia despite optimum 
medical treatment (Kones, R., 2010).   
Many medications are available for the 
treatment of angina. Beta blockers, 
calcium channel blockers, and 
angiotensin-converting enzyme 
inhibitors are often useful in the 
reduction of angina pain. Angioplasty 
and life changes such as smoking 
cessation, weight loss, and stress 
reduction are additional treatment 
options for the patient suffering from 
chronic angina (Mayo Clinic, 2015).  
Despite endless treatment options, 
chronic angina continues to pose 
significant challenges to both patient 
and medical professional.  
The patient diagnosed with chronic 
angina frequently suffers from anxiety, 
fear, pain, and decreased quality of life. 
According to the literature, a continual 
challenge of modern cardiovascular 
medicine is to discover new, effective 
treatments for patients with refractory 
angina pectoris, a clinical condition 
characterized by severe angina despite 
optimal medical therapy (Gennari, 
Gambini, Bassetti, Capogrossi, & 
Pompilio, 2014).   Enhanced external 
counterpulsation (EECP) is approved for 
the management of refractory angina. 
EECP has proven beneficial in the 
decrease of anginal symptoms, 
decreased nitroglycerin use, and 
improvement of exercise tolerance 
(Sharma, Ramsey, & Tak, 2013).    
 
A 62 year old female diagnosed with 
refractory angina pectoris, presents with 
long standing debilitating angina pain. 
The patient’s ability to ambulate and 
preform activities of daily living are 
significantly affected. Daily routine tasks 
such as walking, climbing stairs, or basic 
housekeeping become impossible 
without the patient experiencing chest 
pain (Manchanda et al., 2011). Symptom 
relief could not be achieved through 
standard pharmacological interventions.  
 Over the course of several years all 
treatment options were explored. In 
addition to medication management, 
the patient underwent two coronary 
artery bypass graft surgeries, and 
numerous extensive stent placements. 
Despite continued efforts, the 
debilitating pain and anxiety associated 
with angina continued, affecting all 
aspects of the patient’s life.  
With all other  treatment options 
exhausted, enhanced external 
counterpulsation (EECP) therapy was 
recommended. The treatment was non-
invasive, painless, and beneficial. After 
one month of continued EECP treatment 
new collateral veins were noted to 
several areas of the heart. The patient 
reported a decrease in angina 
symptoms. Additionally, a reduction in 
pharmalogical treatment was noted.  
Implications of nursing 
care related to ECP 
 In June 2002, the United States Food and Drug 
Administration (FDA) approved enhanced external 
counterpulsation (EECP), as an effective treatment for the 
management of refractory angina (Sharma et al., 2013).  
EECP is a non-invasive treatment in the frequency 
reduction and intensity of angina episodes. During EECP 
three pairs of pneumatic cuffs are applied to the lower 
extremities at the levels of the calves and lower and upper 
thighs, cuff inflation and deflation are synchronized with 
the ECG (Kones, R., 2010). Typically, the patient will receive 
thirty five ½ hour sessions over the course of 7 weeks. 
(Kones, R., 2010).  
EECP treatment requires three sets of pneumatic cuffs that 
sequentially contract during diastole, and automatically 
deflate before onset of systole (Kones, R., 2010).  This 
process increases aortic diastolic pressure, while enhancing 
coronary blood flow and central venous return (Sharma et 
al., 2013).  Simply speaking, EECP increases the volume of 
blood returning to the heart, which helps supply more 
oxygen to its starved areas, therefore reducing angina 
(Medscape, 2013). 
According to the literature, EECP is an effective, 
noninvasive, alternative treatment in the patient suffering 
from refractory angina. Benefits of EECP are improved 
ventricular function, systolic BP, coronary perfusion, 
myocardial oxygen balance, and exercise tolerance. 
Successful treatment decreases episodes of angina, sparing 
nitrate use in an impressive proportion of patients (Kones, 
R., 2010). 
 Additionally, EECP is also beneficial in the treatment of 
stable congestive heart failure (CHF) (Sharma et al., 2013).   
Researchers assume that cardiac benefits associated with 
EECP are mediated though vascular endothelial growth 
factor (VEGF) and nitric oxide mediated vasodilatation and 
angiogenesis (Sharma et al., 2013).  
Significance of Pathophysiology 
The nurse should be familiar with the pathological process that 
occurs in the patient suffering from refractory angina.  Becoming 
familiar with the signs and symptoms associated with the disorder 
will enable the nurse to provide accurate and timely care.  
The advanced practice nurse must understand that the patient 
may present with symptoms that are often mistaken for a MI. The 
nurse must be familiar with cardiac enzyme testing. With proper 
knowledge, the nurse can distinguish angina from a MI. Knowledge 
of lab values is significant, as cardiac enzymes will be negative in 
the patient with refractory angina.  
      Conclusion 
Angina pectoris is a clinical syndrome of precordial discomfort 
or pressure due to transient myocardial ischemia without 
infarction (Warnica, 2015). Plaque disruption, thrombosis, 
vasoconstriction, and supply-demand mismatch are all 
contributory factors related to unstable angina (Medscape, 
2013). Angina pectoris occurs as a consequence of increased 
cardiac workload, subsequently myocardial oxygen demand 
exceeds the capability of the coronary arteries to supply an 
acceptable volume of oxygenated blood. (Warnica, 2015).  
Myocardial oxygen demand is primarily determined by heart 
rate, systolic wall tension, and contractility, narrowing of a 
coronary artery typically results in angina that occurs during 
exertion and is relieved by rest (Warnica, 2015). Unstable 
angina falls within the range of clinical presentations referred 
to collectively as acute coronary syndromes (ACS), ranging from 
ST-segment elevation myocardial infarction (STEMI) to non-
STEMI (Medscape, 2013). The patient experiencing ACS should 
be diagnosed with refractory angina when there is no 
detectable release of enzymes and biomarkers of myocardial 
necrosis (Medscape, 2013). 
According to the data, the number of 
patients diagnosed yearly with 
refractory angina continues to increase. 
Pain reduction in this patient population 
is a significant issue faced by clinicians. 
EECP is an effective, noninvasive 
treatment option for the patient 
suffering from refractory angina 
pectoris. Studies show that patients 
treated with EECP have a 25% reduction 
in angina symptoms weekly. According 
to Kohn, 41% of patients treated with 
EECP reported being pain free for 2 
years post treatment (Kohn, 2010). 
The advanced practice nurse, must 
become familiar with all treatment 
options available to the patient suffering 
from angina. EECP should be considered 
as part of the patient’s treatment plan, 
when pharmalogical and surgical options 
have been exhausted. Further education 
to both clinician and patient is needed 
with regard to this effective treatment 
for refractory angina. 
Many medical professionals are 
unfamiliar with EECP therapy, therefore 
EECP is underutilized in the treatment of 
chronic angina. Increased provider 
knowledge related to EECP may provide 
a successful treatment option for the 
patient suffering from chronic angina. 
Research shows, EECP has been safely 
used in the treatment of angina for the 
past two decades, more recently, several 
publications support its efficacy (Sharma 
et al., 2013).    
 
 
 
 
 
